Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rachel Kushner

Dermatology Franklin Square, NY Doctor of Osteopathy

NPI 1558471359 CMS profile 342559

320 Franklin Ave, Franklin Square, NY 11010

Open in the dashboard

General payments

$14,247

444 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Kushner of Franklin Square, NY is reported in the CMS Open Payments database as having received $14,247 across 444 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,334 93
2024 General $5,863 85
2023 General $1,763 78
2022 General $951 49
2021 General $842 45
2020 General $838 39
2019 General $1,656 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Kushner
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Rachel Kushner were reported at $2,334. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Rachel Kushner Dermatology median Middle half National median
2019 $1,656 $454 $129–$1,240 $163
2020 $838 $235 $81–$756 $114
2021 $842 $377 $108–$1,108 $132
2022 $951 $514 $143–$1,391 $149
2023 $1,763 $607 $159–$1,674 $160
2024 $5,863 $751 $204–$1,903 $164
2025 $2,334 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dermavant Sciences, Inc. $4,605 33 payments
  2. AbbVie, Inc. $1,497 71 payments
  3. Lilly USA, LLC $984 47 payments
  4. Novartis Pharmaceuticals Corporation $820 41 payments
  5. Incyte Corporation $736 32 payments
  6. Arcutis Biotherapeutics, Inc. $631 23 payments
  7. Janssen Biotech, Inc. $611 23 payments
  8. Amgen Inc. $387 12 payments
  9. Regeneron Healthcare Solutions, Inc. $386 4 payments
  10. E.R. Squibb & Sons, L.L.C. $347 20 payments
  11. Other $3,243 138 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,534 439 payments
  2. Consulting Fee $3,480 1 payment
  3. Education $210 3 payments
  4. Travel and Lodging $23 1 payment
Products named General payments · program years 2019–2025
  1. VTAMA $4,630 35 payments
  2. TALTZ $859 46 payments
  3. SKYRIZI $739 38 payments
  4. OPZELURA $736 32 payments
  5. TREMFYA $665 21 payments
  6. HUMIRA $571 28 payments
  7. Zoryve $529 18 payments
  8. COSENTYX $525 26 payments
  9. DUPIXENT $386 4 payments
  10. SOTYKTU $347 20 payments
  11. Other $5,730 241 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

775

Median for Dermatology: 534

Drug cost

$103,939

Median for Dermatology: $67,151

Branded share of claims

13.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 29 $64,345
Vtama Tapinarof Brand 18 $25,000
Mometasone Furoate Generic 113 $2,782
Ketoconazole Generic 120 $2,145
Clindamycin Phosphate Generic 54 $1,879
Mupirocin Generic 154 $1,445
Betamethasone Dipropionate Generic 13 $1,027
Metronidazole Generic 24 $969
Clobetasol Propionate Generic 19 $941
Ciclopirox Ciclopirox Olamine Brand 33 $878

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$252,191

Of which drugs: $3,201

Medicare patients

483

Average age 73

Services billed

5,337

301 women, 182 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Diabetes 36%
Ischemic heart disease 29%
Cancer 16%
Osteoporosis 16%
Atrial fibrillation 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 17 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $4,381
$4,381 18 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $201
$201 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $197
$197 — —
SKYRIZI
  • AbbVie, Inc. $173
$173 — —
OPZELURA
  • Incyte Corporation $155
$155 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

444 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record